Generate Biomedicines (GENB) saw its stock plummet 6.25% during intraday trading on Friday, following its initial public offering.
The decline came as the company's shares opened at $15 in their Nasdaq debut, which was below the IPO price of $16. This opening price represents an immediate discount and reflects weaker-than-expected investor demand for the new listing.